Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: Janssen
Details (Identifier #): NCT02407236
Title: CNTO1275UCO3001, A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT02819635
Title: AbbVie M14-234, A Multicenter, Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate the Safety and
Efficacy of ABT-494 for Induction and Maintenance
Therapy in Subjects with Moderately to Severely
Active Ulcerative Colitis
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Georgetson MD, FACG, Michael
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT03006068
Title: M14-533, A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: McDonald M.D., Thomas
Sub-Investigator(s):
Sponsor: Janssen
Details (Identifier #): none
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Gastroenterology
Diagnosis: Gastrointestinal - Ulcerative Colitis
Principal Investigator: Srivatana M.D., Ukorn
Sub-Investigator(s):
Sponsor: AbbVie
Details (Identifier #): NCT01848561
Title: Legacy P11-282, A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)